Bryan Callen

And those gentlemen, after having heard the testimony as well as questioning from the University of Kentucky's representative, which suggested that the FDA would never approve it, began their testimony by saying, It has been asserted that the cardiac risk associated with Ibogaine would disqualify it from consideration by the FDA for clinical trials. That is absolutely and completely incorrect.

And those gentlemen, after having heard the testimony as well as questioning from the University of Kentucky's representative, which suggested that the FDA would never approve it, began their testimony by saying, It has been asserted that the cardiac risk associated with Ibogaine would disqualify it from consideration by the FDA for clinical trials. That is absolutely and completely incorrect.

The question for Ibogaine is not one of the existence of risk. The question is how and if that risk can be mitigated. And assuming that the drug developer can demonstrate that cardiac risk can be safely mitigated and controlled, there is no reason that we would not approve that clinical trial. And with that, the chief objection was nuked.

The question for Ibogaine is not one of the existence of risk. The question is how and if that risk can be mitigated. And assuming that the drug developer can demonstrate that cardiac risk can be safely mitigated and controlled, there is no reason that we would not approve that clinical trial. And with that, the chief objection was nuked.

The question for Ibogaine is not one of the existence of risk. The question is how and if that risk can be mitigated. And assuming that the drug developer can demonstrate that cardiac risk can be safely mitigated and controlled, there is no reason that we would not approve that clinical trial. And with that, the chief objection was nuked.

We had one last piece of due diligence to perform before my commission, which had a membership of nine, was ready to cast a deciding vote to secure the allocation of this $42 million for what was going to be a fabulous leadership opportunity for the people of Kentucky to pioneer an entirely new field of biomedical research.

We had one last piece of due diligence to perform before my commission, which had a membership of nine, was ready to cast a deciding vote to secure the allocation of this $42 million for what was going to be a fabulous leadership opportunity for the people of Kentucky to pioneer an entirely new field of biomedical research.

We had one last piece of due diligence to perform before my commission, which had a membership of nine, was ready to cast a deciding vote to secure the allocation of this $42 million for what was going to be a fabulous leadership opportunity for the people of Kentucky to pioneer an entirely new field of biomedical research.

That will revolutionize how we treat not just addiction, but the problems that we have all sat here and talked about already. And that was the delivery of testimony from Dr. Nolan Williams following the publication of his research in the journal Nature Medicine about the neuroregenerative properties of abrogating the brain as applied to the veteran population with TBI and PTSD.

That will revolutionize how we treat not just addiction, but the problems that we have all sat here and talked about already. And that was the delivery of testimony from Dr. Nolan Williams following the publication of his research in the journal Nature Medicine about the neuroregenerative properties of abrogating the brain as applied to the veteran population with TBI and PTSD.

That will revolutionize how we treat not just addiction, but the problems that we have all sat here and talked about already. And that was the delivery of testimony from Dr. Nolan Williams following the publication of his research in the journal Nature Medicine about the neuroregenerative properties of abrogating the brain as applied to the veteran population with TBI and PTSD.

Unfortunately, there was an election in Kentucky in 2023. My boss, Attorney General Cameron, ran for governor and lost. Andy Beshear was reelected. and a new Kentucky Attorney General took office. And while this new guy had gone in public and had expressed his open-minded willingness to give Ibogaine consideration,

Unfortunately, there was an election in Kentucky in 2023. My boss, Attorney General Cameron, ran for governor and lost. Andy Beshear was reelected. and a new Kentucky Attorney General took office. And while this new guy had gone in public and had expressed his open-minded willingness to give Ibogaine consideration,

Unfortunately, there was an election in Kentucky in 2023. My boss, Attorney General Cameron, ran for governor and lost. Andy Beshear was reelected. and a new Kentucky Attorney General took office. And while this new guy had gone in public and had expressed his open-minded willingness to give Ibogaine consideration,

I had briefed him individually before we had our public announcement in anticipation that he would take office. After he won, I reached out and asked if I could have an opportunity to brief him on all of the developmental energy which had gathered around this project.

I had briefed him individually before we had our public announcement in anticipation that he would take office. After he won, I reached out and asked if I could have an opportunity to brief him on all of the developmental energy which had gathered around this project.

I had briefed him individually before we had our public announcement in anticipation that he would take office. After he won, I reached out and asked if I could have an opportunity to brief him on all of the developmental energy which had gathered around this project.

That energy included the commitment of two significant philanthropic organizations, one of which was the Jurvetson Foundation, led by Stephen and Genevieve Jurvetson, The other was the Stephen and Alexander Cohen Foundation, led by Stephen and Alexander Cohen, and then the third was the Melissa Etheridge Foundation, all of which made commitments to partner with Kentucky to make this come to pass.

That energy included the commitment of two significant philanthropic organizations, one of which was the Jurvetson Foundation, led by Stephen and Genevieve Jurvetson, The other was the Stephen and Alexander Cohen Foundation, led by Stephen and Alexander Cohen, and then the third was the Melissa Etheridge Foundation, all of which made commitments to partner with Kentucky to make this come to pass.

That energy included the commitment of two significant philanthropic organizations, one of which was the Jurvetson Foundation, led by Stephen and Genevieve Jurvetson, The other was the Stephen and Alexander Cohen Foundation, led by Stephen and Alexander Cohen, and then the third was the Melissa Etheridge Foundation, all of which made commitments to partner with Kentucky to make this come to pass.